Innovating Health: Progressing with Caution and Precision

Unforeseen Cardiac Observations Lead to Trial Suspension

On March 23, 2026, Aardvark Therapeutics, a leader in biopharmaceutical innovation, declared a voluntary pause in its pivotal Phase 3 HERO and open-label extension studies for ARD-101, targeting Prader-Willi syndrome, alongside its ARD-201 obesity initiative. This decision underscores the company's commitment to patient safety and adherence to rigorous scientific protocols.

Exploring the Root Cause: Insights from Healthy Volunteer Data

The impetus for this suspension stems from cardiac data gathered during an independent study with healthy individuals, rather than from previous trials involving Prader-Willi syndrome patients. Specifically, two out of eight participants in a cohort receiving a high dose of 1,600 mg of ARD-101 twice daily exhibited QRS increases exceeding 25% from their baseline. Another participant showed a marginal increase below this threshold. In a subsequent cohort, one out of twenty-three participants receiving 800 mg twice daily experienced a transient QRS increase, while another showed a more significant rise. Importantly, these effects were reversible and did not lead to serious adverse events or acute cardiac symptoms.

Understanding the Dose-Response Relationship

Initial evaluations suggest a clear correlation between exposure levels and observed cardiac effects, where higher plasma concentrations of ARD-101 were linked to an elevated risk of QRS prolongation. This crucial finding will guide future adjustments to the trial design and dosing strategies. Recent data concerning ARD-101 were also featured in an issue of Molecular Metabolism, highlighting the scientific rigor behind the therapy's development.

Financial Stability Amidst Clinical Review

Aardvark Therapeutics maintains a strong financial position, reporting $110.0 million in cash, cash equivalents, and short-term investments at the close of 2025. This capital is projected to sustain operations into the second quarter of 2027, providing ample resources for continued research and development during this period of clinical review.

Future Outlook and Therapeutic Focus

As a clinical-stage biopharmaceutical entity, Aardvark Therapeutics is dedicated to advancing small-molecule treatments aimed at controlling hunger in conditions like Prader-Willi syndrome and various metabolic disorders. The company anticipates providing updated guidance on both the ARD-101 and ARD-201 programs in the second quarter of 2026, following discussions and strategic planning with the FDA.